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Abstract A new toxin acting on K channels, maurotoxin 
(MTX), has been purified to homogeneity from the venom of the 
chactoid scorpion Scorpio maurus. MTX is a basic single chain 
34 amino acid residue polypeptide, amidated at its C terminal, 
and crosslinked by four disulfide bridges. It shows 29-68% 
sequence identity with other K+ channel toxins, and presents an 
original disulfide pattern, the last two half-cystine residues ( 3 1 -
34) being connected. Although the first three disulfide bonds have 
not been defined experimentally, modelling based on the 
structure of charybdotoxin favored two combinations out of 
six, one of which has two bridges (3-24 and 9-29) in common 
with the general motif of scorpion toxins. The last bridge would 
connect residues 13 and 19. MTX inhibits the binding to rat brain 
synaptosomal membranes of both |125I]apamin, a SKc a channel 
blocker (IC5 0 5 nM), and [
125I]kaliotoxin, a Kv channel blocker 
(IC5 0 30 pM). MTX blocks the Kvl . l , Kvl.2 and Kvl.3 currents 
expressed in Xenopus oocytes with IC5o of 45, 0.8 and 180 nM, 
respectively. MTX represents a member of a new class of short 
toxins with 4 disulfide bridges, active on voltage-dependent K+ 
channel and also competing with apamin for binding to its 
receptor. 
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1. Introduction 
Venoms from scorpions, snakes, anemones and bees con-
tain numerous polypeptide toxins, binding with high affinity 
to different specific ion channel membrane proteins. These 
toxins have proved to be important tools for studying ion 
channel specificity and functioning [1-3]. In scorpion venoms, 
two main kinds of toxins have been characterized [3]: those 
active on voltage dependent sodium channels, responsible for 
the high toxicity of the venoms, and those active on potassium 
channels, either voltage dependent or calcium activated. The 
sodium channel toxins are made of 60-70 residues, crosslinked 
by four disulfide bridges. The potassium toxins are smaller, 
less than 38 residues and only three disulfide bridges. How-
ever, all scorpion toxins have in common a structural core 
made of an a-helix linked by three covalent bridges to an 
antiparallel two-stranded P-sheet [4]. 
We report in the present paper the purification, from the 
venom of the chactoid Scorpio maurus, of a new toxin named 
maurotoxin (MTX) with new physicochemical and pharmaco-
logical properties. M T X is a small toxin (34 residues) cross-
*Corresponding author. 
linked by four disulfide bridges. M T X blocks the K v l . l , 
K v l . 2 and K v l . 3 channels and competes with both apamin 
and kaliotoxin for binding to rat brain synaptosomes. These 
properties are unique for a scorpion toxin. 
2. Materials and methods 
The venom obtained by electrical stimulation of animals collected 
in the area of Beni Kheddach in Tunisia was extracted with water (50 
mg/ml). The suspension was clarified by centrifugation at HOOOxg 
for 15 min. The supernatant was loaded on a Sephadex G-50 column 
(1.7x 150 cm) equilibrated with 0.1 M ammonium acetate buffer, pH 
8.2. Column effluent was monitored at 280 nm. Fractions were tested 
for toxic activity by intracerebroventricular (i.c.v.) injection to male 
C57BL/6 mice weighing 20 g. The fourth fraction was purified by 
HPLC on a C18 column (4.6X250 mm, 5 urn particle size), eluted 
with a linear 5-25% gradient of 0.1% TFA/acetonitrile in 0.1% TFA/ 
water in 25 min at a flow rate of 1 ml/min. Monitoring was done at 
215 nm. The fraction containing the major toxic activity on mice was 
treated on a C8 column (4.6x250 mm, 5 um) under the same con-
ditions but with a shallower gradient (1-20% in 40 min). The toxic 
peak was collected, lyophilized and stored at —80°C until use. The 
LD50 values are calculated as described previously [5]. 
Electrophoresis of the toxin in nondenaturing conditions was per-
formed essentially according to Reisfeld et al. [6]. The dialyzed sam-
ples (10 itg) were loaded on a 15% (w/v) polyacrylamide gel and run, 
using 0.35 M alanine buffer pH 4.5 on a small slab gel unit (Hoefer 
Scientific instruments, model SE 200s from San Francisco, CA, USA). 
Molecular weights of proteins were determined by SDS-PAGE anal-
ysis under non-reducing conditions as previously described [7] with a 
stacking gel of 3% (w/v) (pH 6.8) and a running gel of 15% (w/v) 
polyacrylamide (pH 8.8). Both types of gel were fixed and stained with 
Coomassie blue and dried under vacuum. 
Amino acid analyses were performed on a Beckman 6300 apparatus 
after hydrolysis of the samples in 6 N HC1, 1% phenol, at 110°C for 
24 h in evacuated tubes using a Picotag work station (Waters). 
Sequence determination was performed on native protein, and 5-
pyridylethylated derivative (5 nmol) obtained by reduction of the 
disulfide bridges with dithioerythritol (60-fold molar excess over di-
sulfide bridges in 250 mM Tris-HCl, 4 mM EDTA, 6 M guanidine, 
pH 8.5, under nitrogen at 40°C for 20 h in the dark, followed by S-
alkylation with 2 ill of 4-vinylpyridine for 20 min at room temper-
ature. Desalting of S-alkylated protein was done by HPLC on a 
microbore column. Also, the alkylated protein (1 nmol) was digested 
with trypsin (5% w/w) for 20 h in 12 ul 125 mM NH4HCO3, pH 8.0 at 
37°C. The peptides were purified on a 140 HPLC system (Applied 
Biosystem) equipped with a C18 PTH-column (2.1 X220 mm, 5 am). 
After an isocratic step of 3 min, the elution gradient was 2-88% 
of solvent B (30% water, 0.1% TFA in acetonitrile) in solvent A 
(0.1% TFA in water) for 60 min, 200 ul/min. Automatic Edman 
degradation was performed on an Applied Biosystem 476 A se-
quencer. 
In order to identify PTH-cystine derivatives that appear in the 
course of sequencing of native MTX, an assay was performed on 
1 nmol of DL-cystine loaded on the sequencer filter and subjected to 
Edman degradation in exactly the same way as a pep tide sample. 
By HPLC, in the standard conditions for PTH identification, the 
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Fig. 1. Purification of MTX form scorpion Scorpio maurus venom. A: Chromatography on Sephadex G-50. Fractions I-VII were collected. 
B: Chromatography of fraction IV on C18 RP-HPLC. C: Chromatography of peak eluting at 14.57 min (IB) on C8-RP-HPLC (see Section 2). 
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Fig. 2. Amino acid sequence of MTX. 'a' corresponds to Edman degradation of reduced and S-alkylated MTX. Cysteine residues were identi-
fied as PTH-5-pyridylethylcysteine. 'b' corresponds to the degradation of the C-terminal peptide obtained by trypsic hydrolysis of 5-alkylated 
MTX. 'c' corresponds to degradation of the native protein: — means no PTH for this step, C corresponds to PTH-cystine (see Section 2). 
'*' means that MTX is C-terminal amidated. 
PTH-cystine derivatives gave two peaks, one coeluting with PTH-Tyr 
and the second eluting 0.66 min later. The main derivative was quan-
tified as 77 pmol of tyrosine, whereas the peak surface of the second 
derivative was five times smaller. When sequencing the native protein, 
these two peaks were both carefully looked for and quantified at each 
step. 
Differently disulfide-paired models of MTX were built with the IN-
SIGHT II, HOMOLOGY, and DISCOVER programs of Biosym 
Technologies, starting from the 3-dimensional structure of charybdo-
toxin [8]. All models were energy-minimized until the RMS derivative 
fell under 0.01 kcal/mol. 
Electrospray mass spectrometry of native protein and C-terminal 
peptide was performed on a VG-Bio-Q (Bio-Tech) in the positive 
mode [9]. The peptide and protein were dissolved at 5 uM concen-
tration in water/methanol (50:50 v/v) containing 1% acetic acid. 
Mono 125I-labeled apamin and [125I]kaliotoxin ([125I]KTX) were 
prepared and used for competition assays with MTX on rat brain 
synaptosomal fraction (P2) as described [10,11]. 
The voltage-dependent Kvl. l , Kvl.2 and Kvl.3 channels were ex-
pressed in Xenopus oocytes by injection of 0.2 ng of cRNA/oocyte. 
cDNAs were cloned from rat brain and were a generous gift of S. 
Alper (Beth Israel Hospital, Harvard Medical School, Boston, MA, 
USA). The plasmids were transcribed using the Ambion Megascript 
kit (Ambion, Texas, USA). The cRNAs were stored frozen at 1 mg/ml 
in water. Defolliculated oocytes were stored in a ND95 medium sup-
plemented with gentamicin 0.1 U/ml (Boehringer, Germany). The 
currents were recorded 2 days after injection and oocytes were bathed 
in a calcium free ND96 medium. Macroscopic Kv currents were re-
corded with the two electrode voltage clamp method using intracel-
lular electrodes filled with KC1 (3 M) and a GeneClamp 500 amplifier 
(Axon Instruments, California, USA). The holding potential was set 
at —80 mV, leak and capacitive currents were subtracted during anal-
ysis. 
3. Results 
3.1. Purification and chemical characterization of MTX 
Water extract (100 OD units at 280 nm) of the venom of 
Scorpio maurus eluted in seven fractions from the Sephadex 
a) b) 
G-50 column (Fig. 1A). Toxic activity tested by i.c.v. injection 
to mice was found in the fourth fraction containing 3 OD 
units. HPLC on a C18 column of this fraction resulted in 
several components (Fig. IB). The major active peak (18%) 
eluting at 14.57 min was shown to be homogeneous by re-
chromatography on a C8 column (Fig. 1C). It was named 
maurotoxin (MTX) and represented about 0.6% of the venom 
water extract. Purity of the MTX was established by gel elec-
trophoresis at pH 4.5 (one band, the most basic protein of the 
venom), SDS-PAGE (one fraction with a Mt of 3.2-3.8 kDa), 
mass spectrometry giving a single component with a MT of 
3612.26 ±0.17. 
The amino acid sequence determined by Edman degrada-
tion on 400 pmol of 5-alkylated MTX and on 700 pmol of 
native MTX is shown in Fig. 2. Hydrolysis of 1 nmol of S-
alkylated MTX by trypsin followed by C18 HPLC and se-
quence analysis of the obtained fractions confirmed the over-
all sequence of MTX and particularly its C-terminal end (Fig. 
2). Amino acid composition analyses of native and alkylated 
MTX are in agreement with the established amino acid se-
quence (data not shown). 
The calculated molecular mass of MTX was 3612.20 for 
MTX-amide and 3613.18 for MTX with a free carboxylic 
acid. The experimental MT of MTX was 3612.26 ±0.17 (see 
above). Moreover, the C-terminal peptide, obtained by trypsin 
proteolysis of 5-pyridylethylated MTX, had a Mr of 653.6 as 
determined by mass spectrometry analysis, which is compat-
ible with a CYGC-NH2 sequence (calculated Mv = 653.83). 
Thus, it was concluded that MTX is C-terminal amidated. 
When sequencing the native protein, no PTH derivative was 
observed at steps 3, 9 and 13 and peaks corresponding to 
cystine derivatives (see Section 2) appeared at steps 19, 24 
and 29. It was not possible to draw any conclusions for steps 
Fig. 3. MTX modeling based on the NMR structure of charybdotoxin. Out of the six possible disulfide pairings deduced from native MTX se-
quencing data, two models 'a' and V were selected, representing the most likely structures (see Section 3). 'c' is the 3-dimensional structure of 
charybdotoxin [8]. 
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Fig. 4. Competitive binding experiments on rat brain synaptosomes. 
A: A 10 pM solution of [125I]apamin was incubated, in a final vol-
ume of 500 |j.l, with rat brain synaptosomes (160 ug of protein) and 
various concentrations of either apamin or MTX. Incubation at 
0°C, for 1 h in a 25 mM Tris-HCl 10 mM KC1 pH 7.2 buffer was 
stopped by centrifugation (llOOOXg, 5 min) and the pellets were 
washed three times in the same cold buffer. B: A 40 pM solution of 
[125I]KTX (1-37) was incubated in a final volume of 200 ul with 
synaptosomes (30 ug of protein) and various concentrations of ei-
ther KTX or MTX. Incubation at 25°C, for 1 h in a 25 mM Tris-
HCl 50 mM NaCl 0.1% BSA pH 7.4 buffer was stopped by centri-
fugation (HOOOXg, 5 min) and the pellets washed twice with 1 ml 
of cold washing buffer (20 mM Tris-HCl 150 mM NaCl 0.1% BSA 
pH 7.4). The radioactivity bound to the membranes was counted. 
Bo is the binding of [125I]toxin in the absence of competitor, B is 
the binding in the presence of one of the native toxins. Non-specific 
binding was less than 10% for [125I]apamin and less than 25% for 
[125I]KTX (1-37). The values are the means of triplicate (A) or du-
plicate (B) experiments. The standard error of the mean of the data 
was around 5%. 
31 and 34, because of the low signal/noise ratio. From these 
results, we could assume that the first three half-cystines at 
positions 3, 9, 13 were paired with the half-cystines 19, 24 and 
29. Therefore, the fourth bridge was predicted to be between 
half-cystines 31 and 34. From these data, there remained only 
six different possible pairings for the three first disulfide 
bridges. Models corresponding to these pairings were built 
taking the charybdotoxin 3-dimensional structure as template 
[8]. Only two of these models had conserved their oc-helix and 
the commonly conserved pattern found in scorpion toxins. 
They also gave the best score in Ramachandran plot after 
energy minimization. The two models correspond to disulfide 
pairings 3-24, 9-29, 13-19, 31-34, and 3-29, 9-24, 13-19, 3 1 -
34 (Fig. 3a,b). 
3.2. Biological activity 
MTX was toxic with a LD5o of 100 ng/20 g mouse as 
determined by i.c.v. injection. MTX competed fully with 
[125I]apamin and [125I]KTX for their binding to rat brain syn-
aptosomal membranes with IC50 of 5 nM and 30 pM respec-
tively (Fig. 4). In the same conditions, the IC50 for native 
apamin and KTX were respectively 5 and 10 pM. These re-
sults suggest that MTX recognizes both apamin and kaliotox-
in receptor sites with high affinity. MTX blocked the Kvl. l , 
Kvl.2 and Kvl.3 currents with various affinities. The most 
potent effect concerned Kvl.2 with an IC50 of 0.8±0.2 nM 
(« = 6). Fig. 5 describes the blockade of Kvl.2 currents by 
incremental MTX concentrations (0.2, 1 and 5 nM). The 
blockade was fully reversible in 40 min. Similar experiments 
performed with Kvl.l and Kvl.3 currents gave IC5o of 45 ± 6 
nM (« = 4) and 180 nM (« = 2), respectively (not illustrated). 
4. Discussion 
MTX is a new basic single chain polypeptide, composed of 
34 amino acid residues, crosslinked by four disulfide bridges. 
It has been purified to homogeneity from Scorpio maurus 
venom. MTX is amidated at its C-terminal end. MTX is a 
newly characterized scorpion toxin with 8 half-cystine residues 
acting on K+ channels. Electrophysiological experiments on 
the MTX induced blockade of Kvl. l , KV1.2 and Kvl.3 cur-
rents revealed pharmacological properties different from 
KTX. Kaliotoxin has been described as a potent blocker of 
Kvl.3 (IC50 of 0.4 nM) and Kvl.l (IC50 of 46 nM), whereas it 
has a low affinity (IC50 > 1 mM) to Kvl.2 [12,13]. The MTX 
induced blockade mimicked the kaliotoxin effects on Kvl. l , 
whereas it blocked Kvl.3 with a IC50 (180 nM) 500 times 
higher than kaliotoxin. Interestingly, MTX appears to be a 
potent blocker of the Kvl.2 current (IC50 of 0.8 nM), appar-
ently more active than other scorpion toxins active on Kvl.2 
[12]. On the basis of these properties, MTX is considered as 
the first member of a new group of K+ channel toxins. It 
presents (Fig. 6) 38-68% sequence identity with toxins acting 
on voltage dependent K+ channels, and 29% identity with 
toxins acting on apamin sensitive potassium channels, leiuro-
toxin I and P05 [14,15]. Like these toxins, MTX lacks four or 
five amino acid residues at its N-terminal part, and is able to 
compete with [125I]apamin on rat brain synaptosomes. MTX 
presents two basic residues at positions 20-21 (Fig. 6) that 
could participate in the apamin-like activity and play the 
same function as the doublet in positions 13-14 of P05 
[16,17]. If sequence alignments are in accordance with confor-
mations, the positions 20-21 would be located at the end of 
an oc-helix, as in apamin [18]. MTX also has the two basic 
residues at positions 13 and 20, considered important for LTX 
in its apamin-like activity [14]. In contrast, for P01, a scorpion 
toxin with a low affinity for the apamin site (in the |xM range), 
positions 13, 20 and 21 are occupied by Glu, Ser and Thr 
residues, respectively [19]. 
Six of 8 cysteine residues of MTX (3, 9, 13, 24, 29 and 31) 
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Fig. 5. Blockade of the Kvl.2 current in Xenopus oocytes induced by MTX. Control panel: Kvl.2 currents produced in voltage clamped oo-
cytes by a series of voltage steps from —40 mV up to 0 mV. Application of MTX (0.2, 1, and 5 nM) decreased currents by 31%, 85% and 
100%, respectively. The 5 nM induced blockade is partly reversed by a 18 min wash. Dose-response effects of MTX are determined by repeat-
ing a test pulse (0 mV) during application of incremental MTX concentrations. 
occupy conserved positions of the common sequential motif 
which was reported to be shared by all scorpion toxins includ-
ing those crosslinked by four disulfide bridges [4], i.e. 
[...]C[...]CXXXC[...]GXC[...]CXC[...]. However, with two 
bridges connecting successive half-cystine residues (Cys-13-
19 and Cys-31-34), the covalent structure of MTX has no 
equivalent in other scorpion neurotoxins. MTX has in com-
mon with PI1, a toxin active on Shaker B K+ channels [20], 
eight half-cystines in homologous positions and also the ab-
sence of the conserved glycine residue in position 28 (Fig. 6). 
In position 29 MTX presents a similar alanine residue as in 
noxiustoxin and margatoxin. These particularities may play a 
role in the unexpected disulfide organization. Data based on 
careful examination of PTH-Cys obtained during native MTX 
sequencing suggested that the first three half-cystines were 
bridged to the next three half-cystines: thus the pairing of 
Cys-31 and -34 was deduced. Six MTX models corresponding 
to the possible pairings of the three other disulfide bonds 
between Cys-3, -9, -13 and Cys-19, -24 and -29 were built 
taking the charybdotoxin as a template. The two best models 
are shown in Fig. 3a,b. We could not discriminate between 
these two models on purely geometric or energetic criteria. It 
should be noticed, however, that model a was the only one 
showing as many as two homologous disulfides with charyb-
dotoxin and thus fitted the best with the overall scorpion 
neurotoxin family structure. The disulfide pairings of MTX 
in model a were Cys-3-24, Cys-9-29, Cys-13-19, and Cys-31-
34. In the charybdotoxin molecule, we observed that substi-
tution of Gly-26 (homologous of Gly-22 in MTX) into an Ala 
residue could occur only at the expense of disturbing the 
structure, since there is no room for the Ala side-chain methyl 
group, which otherwise would bump the Cys-17 side-chain. In 
the model of MTX, however, it seems that Ala-22 could find 
its place since the Cys-13 (homologous of Cys-17 in charyb-
dotoxin) side-chain is oriented differently, due to the pairing 
13-19 instead of 13-31. In fact, the Cys-13 habitual partner 
(Cys-31) is making a bridge with the near residue Cys-34, 
which has no equivalent in other scorpion neurotoxins. More-
over, during model minimization, the initial almost straight-
shaped a-helix bent progressively with the Pro-12 residue as a 
hinge; this could afford additional accommodation for the 
Ala residue, as observed in the 3-dimensional structure deter-
mination of noxiustoxin [21]. When a synthetic MTX was 
constructed and its disulfide pairing determined, the covalent 
structure deduced was identical to model a [22]. 
The first bridge brings together the two regions where se-
quence similarity is the highest within the longest toxins (Fig. 
6). This clustered region comprising the homologous amino 
acid residues in the N-terminal sequence (positions 6-11 of 
Fig. 6 for KTX and MTX) and in the C-terminal sequence 
(positions 30-34) is suggested to be involved in the binding of 
KTX to K+ channels [23]. It notably contains the lysine res-
idue (position 30 of Fig. 6) which was shown to be an essen-
tial element for the activity of charybdotoxin [24]. The com-
petition between MTX and [125I]KTX in binding to rat brain 
synaptosomal membranes can be associated more precisely 
with these homologous amino acid residues. 
MTX shows maximum sequence identity with PI1 (Fig. 6). 
However, the disulfide pairing of these two toxins appears to 
be different, only two of the bridges being identical. This 
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Fig. 6. Sequence comparison of different scorpion toxin K+ channel inhibitors. On the basis of amino acid sequence, MTX may represent a 
link between voltage dependent potassium channel toxins and apamin-like toxins, and be an element of a new group. The sequences, taken 
from [14,15,20,25,26], have been aligned with respect to the six half-cystine residues. The conformational elements presented at the top of the 
sequences refer to the structure of charybdotoxin [8]. The percentage similarity to MTX is indicated. Boxed residues in all other sequences than 
MTX are identical or homologous to those in the MTX sequence. 
finding may be of interest regarding the scorpion toxin struc-
ture-activity relationships. 
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